Personalized medicine and tobacco-related health disparities: Is there a role for genetics?

Annals of Family Medicine

Volumn 9, Issue 4, 2011, Pages 366-371

  Carlsten, Chris ^a   Halperin, Abigail ^b   Crouch, Julia ^b   Burke, Wylie ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Genetics; Health status disparities; Personalized medicine; Smoking

Indexed keywords

ARTICLE; GENETICS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; METHODOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; SMOKING; SMOKING CESSATION; SOCIOECONOMICS;

HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; SMOKING; SMOKING CESSATION; SOCIOECONOMIC FACTORS;

EID: 79960472732     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1244     Document Type: Article

References (70)

1. Landman A, Glantz SA. Tobacco industry efforts to undermine policy-relevant research. Am J Public Health. 2009;99(1):45-58.
2. World Health Organization. Tobacco Industry Interference With Tobacco Control. Geneva: WHO; 2008.
3. Warner K. Tobacco policy research: insights and contributions to public health policy. In: Warner KE, Isaacs SL, Knickman JR, eds. Tobacco Control Policy. San Francisco, CA: Jossey-Bass; 2006:3-86.
4. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. Geneva: WHO; 2008.
5. Schroeder SA. Shattuck Lecture. We can do better-improving the health of the American people. N Engl J Med. 2007;357(12): 1221-1228.
6. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med. 2000;18(4):305-311.
7. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(44):1227-1232.
8. Fiore M, Jaén CR, Baker TB, et al. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A US Public Health Service report. Am J Prev Med. 2008;35(2):158-176.
9. Warner KE, Mackay JL. Smoking cessation treatment in a publichealth context. Lancet. 2008;371(9629):1976-1978.
10. Curry SJ, Keller PA, Orleans CT, Fiore MC. The role of health care systems in increased tobacco cessation. Annu Rev Public Health. 2008;29:411-428.
11. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31(1):52-61.
12. Centers for Disease Control and Prevention (CDC), Offi ce on Smoking and Health. Reducing Tobacco Use: A Report of the Surgeon General. 2000. http://www.cdc.gov/tobacco/data_statistics/sgr/2000/highlights/tobacco/index.htm. Accessed May 19, 2009.
13. Collins FS. Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med. 1999;341(1):28-37.
14. Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet B Neuropsychiatr Genet. 2003;118B(1):48-54.
15. Caporaso N, Gu F, Chatterjee N, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE. 2009;4(2):e4653. doi:10.1371/journal.pone.0004653.
16. Mwenifumbo J, Tyndale RF. Molecular genetics of nicotine metabolism. Handb Exp Pharmacol. 2009;(192):235-259.
17. Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008;9(8):738-784.
18. Personalized Medicine Coalition. http://www.personalizedmedicinecoalition. org/about/about-personalized-medicine/personalizedmedicine- 101. Accessed Dec 31, 2008.
19. Snyderman R. Personalized medicine means planning for your future health. Analyzing a patient's health risks and focusing on prevention and health planning are key components of the 21st century's new health care. Health News. 2008;14(11):6-7.
20. Gammon K. Leroy Hood: look to the genome to rebuild health care. Wired. Sep 22, 2008.
21. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med. 2003;349(10):996-998.
22. O'Neill SC, McBride CM, Alford SH, Kaphingst KA. Preferences for genetic and behavioral health information: the impact of risk factors and disease attributions. Ann Behav Med. 2010;40(2):127-137.
23. Hall WD, Gartner CE, Carter A. The genetics of nicotine addiction liability: ethical and social policy implications. Addiction. 2008;103 (3):350-359.
24. McBride CM, Bepler G, Lipkus IM, et al. Incorporating genetic susceptibility feedback into a smoking cessation program for African- American smokers with low income. Cancer Epidemiol Biomarkers Prev. 2002;11(6):521-528.
25. Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin defi ciency. Ann Behav Med. 2007;33(1):22-28.
26. Hishida A, Terazawa T, Mamiya T, et al. Effi cacy of genotype notifi - cation to Japanese smokers on smoking cessation-an intervention study at workplace. Cancer Epidemiol. 2010;34(1):96-100.
27. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598-600.
28. Uhl GR, Liu QR, Drgon T, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008;65(6):683-693.
29. Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol. 2007;78:225-246.
30. Stephens SH, Logel J, Barton A, et al. Association of the 5¢-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr Res. 2009;109 (1-3):102-112.
31. Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther. 2006;80(3): 282-297.
32. Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol. 2010;66(3):239-251.
33. Lerman C, Jepson C, Wileyto EP, et al. Genetic variation in nicotine metabolism predicts the effi cacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther. 2010;87(5):553-557.
34. Gordon LG, Hirst NG, Young RP, Brown PM. Within a smokingcessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness? Cost Eff Resour Alloc. 2010;8:18.
35. Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smokingcessation treatment. Pharmacogenomics J. 2008;8(6):391-399.
36. Welton NJ, Johnstone EC, David SP, Munafò MR. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res. 2008;10(1):231-240.
37. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-304.
38. Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N Engl J Med. 2010;362(21):2001-2011.
39. Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract. 2000;49(9):796-804.
40. Gené-Badia J, Ascaso C, Escaramis-Babiano G, et al. Personalised care, access, quality and team coordination are the main dimensions of family medicine output. Fam Pract. 2007;24(1):41-47.
41. Stange KC. The generalist approach. Ann Fam Med. 2009;7(3): 198-203.
42. Safran DG. Defi ning the future of primary care: what can we learn from patients? Ann Intern Med. 2003;138(3):248-255.
43. Candib LM, Gelberg L. How will family physicians care for the patient in the context of family and community? Fam Med. 2001; 33(4):298-310.
44. Fuertes JN, Mislowack A, Bennett J, et al. The physician-patient working alliance. Patient Educ Couns. 2007;66(1):29-36.
45. Stange KC. Power to advocate for health. Ann Fam Med. 2010; 8(2):100-107.
46. Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2008;34(4):426-432.
47. Fagan P, Moolchan ET, Lawrence D, Fernander A, Ponder PK. Identifying health disparities across the tobacco continuum. Addiction. 2007;102(Suppl 2):5-29.
48. Lasser K. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;(284):2606-2610.
49. Niederdeppe J, Fiore MC, Baker TB, Smith SS. Smoking-cessation media campaigns and their effectiveness among socioeconomically advantaged and disadvantaged populations. Am J Public Health. 2008;98(5):916-924.
50. Barbeau EM, Krieger N, Soobader MJ. Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000. Am J Public Health. 2004;94(2):269-278.
51. Fu SS, Kodl MM, Joseph AM, et al. Racial/Ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1640-1647.
52. Shelley D, Cantrell MJ, Moon-Howard J, Ramjohn DQ, VanDevanter N. The $5 man: the underground economic response to a large cigarette tax increase in New York City. Am J Public Health. 2007; 97(8):1483-1488.
53. Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington DC: Institute of Medicine; 2003.
54. Sachs DP, Hodgkin JE, Bostrom AG. Improving treatment outcome in the face of increasingly severe nicotine dependence in patients seeking tobacco-dependence treatment. Chest. 2008;134(s53002).
55. Fu SS, Burgess DJ, Hatsukami DK, et al. Race and nicotine replacement treatment outcomes among low-income smokers. Am J Prev Med. 2008;35(6)(Suppl):S442-S448.
56. Woolf SH, Johnson RE. The break-even point: when medical advances are less important than improving the fi delity with which they are delivered. Ann Fam Med. 2005;3(6):545-552.
57. Lawlor DA, Frankel S, Shaw M, Ebrahim S, Smith GD. Smoking and ill health: does lay epidemiology explain the failure of smoking cessation programs among deprived populations? Am J Public Health. 2003;93(2):266-270.
58. Wisconsin Department of Health and Human Services. Wisconsin Tobacco Control Disparities Strategic Planning Workshop. Bringing Everyone Along: A Strategic Plan to Identify and Eliminate Tobacco- Related Disparities in Wisconsin. Wisconsin Department of Health and Human Services; 2002.
59. Niederdeppe J, Kuang X, Crock B, Skelton A. Media campaigns to promote smoking cessation among socioeconomically disadvantaged populations: what do we know, what do we need to learn, and what should we do now? Soc Sci Med. 2008;67(9):1343-1355.
60. Shortell SM, Swartzberg J. The physician as public health professional in the 21st century. JAMA. 2008;300(24):2916-2918.
61. Hall WD. A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tob Control. 2007;16(1): 53-58.
62. Siahpush M, Wakefield MA, Spittal MJ, Durkin SJ, Scollo MM. Taxation reduces social disparities in adult smoking prevalence. Am J Prev Med. 2009;36(4):285-291.
63. Ramsey SA, Gold ES, Aderem A. A systems biology approach to understanding atherosclerosis. EMBO Mol Med. 2010;2(3):79-89.
64. Korkola J, Gray JW. Breast cancer genomes-form and function. Curr Opin Genet Dev. 2010;20(1):4-14.
65. Gresham V, McLeod HL. Genomics: applications in mechanism elucidation. Adv Drug Deliv Rev. 2009;61(5):369-374.
66. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2):111-137.
67. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277-287.
68. Mallal S, Phillips E, Carosi G, et al; PREDICT-1 Study Team. HLAB* 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
69. Hall W, Madden P, Lynskey M. The genetics of tobacco use: methods, fi ndings and policy implications. Tob Control. 2002;11(2):119-124.
70. Graham H. Why social disparities matter for tobacco-control policy. Am J Prev Med. 2009;37(2)(Suppl):S183-S184.